Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Regeneron Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: Miljenko Zuanic who wrote (722)	12/20/2002 1:50:33 AM
From: Miljenko Zuanic	Respond to of 3559

Very, very strong endorsement of the anti-VEGF therapy for AMD and DME. If I take (my) relation of the deal versus market value (1:10), than +$800M Eyetech's Macugen deal speak for itself. Guys, speed up with VEGF-trap! Miljenko Pfizer To Pay Eyetech $100 Million In Deal Wednesday December 18, 6:23 am ET NEW YORK -(Dow Jones)- Pfizer Inc. (NYSE:PFE - News) and Eyetech Pharmaceuticals Inc. signed an agreement to develop and sell Eyetech's Macugen, a potential treatment for age-related macular degeneration and diabetic macular edema, which both cause blindness. In a press release Wednesday, Pfizer said it will make initial payments of $ 100 million, with $195 million in possible milestone payments, based on gaining regulatory approvals. Privately held Eyetech also has the potential to receive up to $450 million in additional milestone payments, based on successful commercialization and sales levels. Pfizer, which reported revenue of $25.18 billion for the nine months ended Sept. 29, will fund the majority of the ongoing development for the drug used in these indications.

To: Miljenko Zuanic who wrote (722)	12/21/2002 10:00:37 PM
From: keokalani'nui	Read Replies (1) \| Respond to of 3559

Abstr now avail on-line: Nat Med 2002 Dec 16; [epub ahead of print] Related Articles, Links Cytokine traps: multi-component, high-affinity blockers of cytokine action. Economides AN, Carpenter LR, Rudge JS, Wong V, Koehler-Stec EM, Hartnett C, Pyles EA, Xu X, Daly TJ, Young MR, Fandl JP, Lee F, Carver S, McNay J, Bailey K, Ramakanth S, Hutabarat R, Huang TT, Radziejewski C, Yancopoulos GD, Stahl N. [1] Department of BioMolecular Science, Regeneron Pharmaceuticals, Inc., Tarrytown, New York, USA [2] A.N.E. and L.R.C. contributed equally to this study. Cytokines can initiate and perpetuate human diseases, and are among the best-validated of therapeutic targets. Cytokines can be blocked by the use of soluble receptors; however, the use of this approach for cytokines such as interleukin (IL)-1, IL-4, IL-6 and IL-13 that use multi-component receptor systems is limited because monomeric soluble receptors generally exhibit low affinity or function as agonists. We describe here a generally applicable method to create very high-affinity blockers called 'cytokine traps' consisting of fusions between the constant region of IgG and the extracellular domains of two distinct cytokine receptor components involved in binding the cytokine. Traps potently block cytokines in vitro and in vivo and represent a substantial advance in creating novel therapeutic candidates for cytokine-driven diseases. PMID: 12483208 [PubMed - as supplied by publisher]